Last reviewed · How we verify

PMG Pharm Co., Ltd — Portfolio Competitive Intelligence Brief

PMG Pharm Co., Ltd pipeline: 3 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 3 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
LAYLA tablet LAYLA tablet marketed SSRI Serotonin transporter Psychiatry
CENATONE tablet CENATONE tablet marketed
JOINS tablet JOINS tablet marketed Orthopedics/Rheumatology
PG201 tablet PG201 tablet phase 3 SGLT2 inhibitor SGLT2 Diabetes
PK101-002 PK101-002 phase 3 HIF-1α inhibitor HIF-1α Oncology
PK101 PK101 phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
  2. Qilu Pharmaceutical Co., Ltd. · 2 shared drug classes
  3. Astellas Pharma Inc · 2 shared drug classes
  4. Beni-Suef University · 2 shared drug classes
  5. EMS · 2 shared drug classes
  6. Pharmaceutical Project Solutions, Inc. · 2 shared drug classes
  7. Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 2 shared drug classes
  8. Sun Pharmaceutical Industries Limited · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for PMG Pharm Co., Ltd:

Cite this brief

Drug Landscape (2026). PMG Pharm Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pmg-pharm-co-ltd. Accessed 2026-06-10.

Related